Are you sure you want to leave?
15 September 2021
According to a new meta-analysis by Csomor et al. (2019),1 active vitamin D (AVD) analogues may not be optimal treatments for secondary hyperparathyroidism (SHPT) in non-dialysis chronic kidney disease (ND-CKD).1,2
Csomor et al. performed a systematic review and meta-analysis of six randomised controlled trials (RCTs) to evaluate the effect of AVD analogues on hypercalcaemia in patients with ND-CKD and SHPT.1 A summary of the systematic review and meta-analysis on AVD analogues is provided below.
A detailed summary of the meta-analysis, as well as other studies that highlight unmet needs in the treatment of SHPT, can be found in a review article at the European Medical Journal website.
1. Csomor P et al. Poster presented at: ISPOR Europe; 2019 November 2–6; Copenhagen, Denmark.
2. EMJ Nephrol. 2020;8(Suppl 3):2–10.
You are viewing a website from Vifor Pharma. This material is only intended for healthcare professionals (“HCPs”) from Europe. If you are not the intended audience, please leave this website. By checking the box, you acknowledge that you are a HCP from Europe. Approval conditions for products may vary from country to country. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.
I am residing in:
Bitte verwenden Sie als Benutzernamen die E-Mail Adresse, welche Sie bei der Registration angegeben hatten. Falls Sie das Passwort vergessen haben, können Sie sich einen Reaktivierungslink zustellen lassen. Alternativ ist für bereits registrierte Health Professionals auch eine Anmeldung mit der HPC-Card von FMH oder pharmaSuisse möglich.